Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):e15-8. doi: 10.1097/QAI.0b013e3182a5c8d4.

Authors

Paul G Farnham¹, David R Holtgrave, Chaitra Gopalappa, Angela B Hutchinson, Stephanie L Sansom

Affiliation

¹ *Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA; †Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and ‡Futures Institute, Glastonbury, CN.

PMID: 24047975
DOI: 10.1097/QAI.0b013e3182a5c8d4

No abstract available

Publication types

Letter

MeSH terms

Anti-HIV Agents / therapeutic use*
Cost-Benefit Analysis
HIV Infections / diagnosis*
HIV Infections / drug therapy
HIV Infections / economics
HIV Infections / prevention & control*
Humans
Monte Carlo Method
Quality-Adjusted Life Years*
Treatment Outcome

Substances

Anti-HIV Agents